1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 3: 
Effect of advanced imaging on outcome and safety
WUS[advanced] (n = 68)Non-WUS[advanced] (n = 60)OR (95% CI), P Value
A) WUS treated after CTP or MRI [advanced] compared with the remaining WUS [non-advanced]
    mRS 0–2 (3 mo) (No.) (%)32 (47.1)14 (23.3)2.92 (1.32–6.45), .006
    In-hospital mortality (No.) (%)5 (7.5)11 (18.3)0.36 (0.11–1.12), .106
    All-cause mortality (3 mo) (No.) (%)11 (16.2)18 (30.0)0.45 (0.19–1.07), .090
    sICH (No.) (%)1 (1.5)2 (3.4)0.43 (0.04–4.95), .599
DUS[advanced] (n = 63)Non-DUS[advanced] (n = 102)
B) DUS treated after CTP and MRI [advanced] compared with the remaining DUS [non-advanced]
    mRS 0–2 (3 mo) (No.) (%)23 (36.1)22 (21.6)2.09 (1.03–4.25), .048
    In-hospital mortality (No.) (%)8 (12.7)30 (30.0)0.34 (0.14–0.82), .013
    All-cause mortality (3 mo) (No.) (%)13 (20.6)39 (38.2)0.42 (0.20–0.88), .025
    sICH (No.) (%)2 (3.3)8 (8.1)0.39 (0.08–1.90), .320
WUS[mri] (n = 47)Non-WUS[mri] (n = 81)
C) WUS treated after MRI [mri] compared with the remaining WUS [non-mri]
    mRS 0–2 (3 mo) (No.) (%)24 (51.1)22 (27.2)2.80 (1.28–6.10), .008
    In-hospital mortality (No.) (%)2 (4.3)14 (17.3)0.22 (0.05–1.04), .049
    All-cause mortality (3 mo) (No.) (%)6 (12.8)23 (28.4)0.37 (0.14–1.01), .050
    sICH (No.) (%)1 (2.2)2 (2.6)0.84 (0.07–9.68), 1.000
DUS[mri] (n = 52)Non-DUS[mri] (n = 113)
D) DUS treated after MRI [mri] compared with the remaining DUS [non-mri]
    mRS 0–2 (3 mo) (No.) (%)20 (38.5)25 (22.1)2.20 (1.06–4.55), .038
    In-hospital mortality (No.) (%)8 (15.4)30 (27.0)0.49 (0.21–1.17), .115
    All-cause mortality (3 mo) (No.) (%)12 (23.1)40 (35.4)0.55 (0.27–1.17), .149
    sICH (No.) (%)2 (4.0)8 (7.3)0.53 (0.11–2.62), .726
  • Note:—sICH indicates symptomatic intracranial hemorrhage.